Today, a single patent can contain tens of thousands of biological sequences, many of which are hidden in plain sight. These so-called \u2018megapatents\u2019 raise the stakes for how biological sequence data is captured, interpreted and used in decision-making.<\/p>\n
Relying solely on electronic sequence listings can lead to costly blind spots for patent professionals and researchers. That\u2019s why curated, context-rich data, like that provided by GENESEQ,<\/a> is no longer a luxury but a necessity.<\/p>\n This blog explores how megapatents expose the limitations of automated sequence capture and why GENESEQ\u2019s human-curated approach is essential for accurate freedom-to-operate (FTO) assessments, competitive intelligence and strategic intellectual property (IP) planning.<\/p>\n Read more about how GENESEQ can strengthen your IP strategy<\/a> in our factsheet.<\/p>\n Before the mid-2000s, biological sequence data<\/a> in patents, when present, were typically embedded within the patent specification. The GENESEQ editorial team manually extracted and annotated these sequences to ensure accuracy and completeness. Formal sequence listings formed part of the patent specification, and the sequence data was manually captured by the GENESEQ team of data capture analysts.<\/p>\n Around that time, the World Intellectual Property Office (WIPO) began publishing electronic sequence listings, a format that has since been gradually adopted by other patent authorities. These listings are intended to capture all sequences referenced in a patent, whether in the claims, examples or disclosure sections. However, in practice, they are often incomplete or entirely absent. As a result, manual curation is still required to ensure a full and accurate representation of the sequence content.<\/p>\n This challenge is amplified by the emergence of so-called megapatents \u2014\u00a0single patent filings that disclose vast numbers of genetic sequences<\/strong>. These patents typically:<\/p>\n This practice has raised concerns among scientists and legal experts alike. Megapatents can create legal uncertainty<\/strong>, stifle innovation<\/strong> and limit access to foundational genetic information<\/strong>, especially when the underlying data is incomplete or poorly annotated.<\/p>\nWhat is a megapatent?<\/strong><\/h3>\n
\n
Megapatents and GENESEQ: Why manual work matters<\/strong><\/h3>\n